Dexcom has announced positive results from a recent study on its G7 continuous glucose monitor (CGM), which demonstrated improved blood sugar control in type 2 diabetes patients not using insulin. Presented at the American Diabetes Association's annual meeting, the 26-week study involved 283 participants, half of whom used the G7 monitor while the others relied on traditional finger-prick testing. Results showed that those using the G7 achieved an average reduction of 1.6% in blood sugar levels, outperforming the control group by 0.9%. The benefits were particularly notable among participants taking GLP-1 medications, who recorded a 1.4% decline compared to 0.2% in the control group. The study's principal investigator, Tamara Oser, expressed hope that these findings would influence the standard of care, improving access to CGMs for all type 2 diabetes patients. Dexcom's CEO, Jake Leach, emphasized the clinical and economic advantages of CGMs, suggesting that these results could lead to broader recognition of their benefits within the healthcare system.